Does anti-p53 antibody status predict for clinical outcomes in metastatic colorectal cancer patients treated with fluoropyrimidine, oxaliplatin, plus bevacizumab as first-line chemotherapy?

BACKGROUND: TP53 gene mutation is widely known as one of the determinants of impaired chemosensitivity. p53 is a tumor-suppressor protein in humans encoded by the TP53 gene. Some studies have shown that TP53 gene mutation and accumulation of the p53 protein are closely related with serum anti-p53 an...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:BMC Cancer
Autors principals: Osumi, Hiroki, Shinozaki, Eiji, Suenaga, Mitsukuni, Kumekawa, Yosuke, Ogura, Mariko, Ozaka, Masato, Matsusaka, Satoshi, Chin, Keisho, Yamamoto, Noriko, Mizunuma, Nobuyuki
Format: Artigo
Idioma:Inglês
Publicat: BioMed Central 2015
Matèries:
Research Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4618932/
https://ncbi.nlm.nih.gov/pubmed/26490659
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-015-1751-6
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars